Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
Oncology (Williston Park). 2024 Mar 1;38(3):104-106. doi: 10.46883/2024.25921014.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7...
Source: Oncology (Williston Park, N.Y.) - March 22, 2024 Category: Cancer & Oncology Authors: Fiza Khan Foorquan Hashmi Nerses Ghahramanyan Elen Baloyan Gevorg Tamamyan Marina Konopleva Naveen Pemmaraju Astghik Voskanyan Source Type: research

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Leukemia, Published online: 22 March 2024; doi:10.1038/s41375-024-02209-7Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia (Source: Leukemia)
Source: Leukemia - March 22, 2024 Category: Hematology Authors: Thomas Burmeister Aeint-Steffen Str öh Britta Kehden Heiko Trautmann Claus Meyer Rolf Marschalek Patrizia Larghero Stefan Schwartz Bj örn Steffen Bernd Spriewald Thomas Heinicke Nadja J äkel J örg Westermann Kathrin Nachtkamp Andreas Viardot Max S. To Source Type: research

The Eμ-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia
Leukemia, Published online: 22 March 2024; doi:10.1038/s41375-024-02221-xThe Eμ-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia (Source: Leukemia)
Source: Leukemia - March 22, 2024 Category: Hematology Authors: Ali Farrokhi Tanmaya Atre Jenna Rever Mario Fidanza Wendy Duey Samuel Salitra Junia Myung Meiyun Guo Sumin Jo Anuli Uzozie Fatemeh Baharvand Nina Rolf Franziska Auer Julia Hauer Stephan A. Grupp Patrice Eydoux Philipp F. Lange Alix E. Seif Christopher A. Source Type: research

Diagnostic significance of cerebrospinal fluid flow cytometry in Chinese children with B lineage acute lymphoblastic leukemia
Central nervous system leukemia (CNSL) is one of the major causes of the poor prognosis of childhood leukemia. We aimed to compare the sensitivity of cytomorphology (CM) and flow cytometry (FCM) in diagnosing ... (Source: BMC Pediatrics)
Source: BMC Pediatrics - March 22, 2024 Category: Pediatrics Authors: Xue Tang, Huirong Mai, Lulu Wang, Shiyang Chen, Fen Chen, Tonghui Li, Yi Liu, Guichi Zhou, Shilin Liu, Ying Wang, Sixi Liu, Xiaoying Fu and Feiqiu Wen Tags: Research Source Type: research

Fatigue in children who have recently completed treatment for acute lymphoblastic leukemia: a longitudinal study
This study examined fatigue in patients treated for childhood acute lymphoblastic leukemia (ALL) over a 2-year period (3- to 27-months post-treatment completion), from the perspective of children and parent ca... (Source: Health and Quality of Life Outcomes)
Source: Health and Quality of Life Outcomes - March 22, 2024 Category: International Medicine & Public Health Authors: S. Walsh, M. Mulraney, M.C. McCarthy and Cinzia R. De Luca Tags: Research Source Type: research

Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of children being treated for acute lymphoblastic leukemia
CONCLUSIONS: Lipid abnormalities in children being treated for ALL may be associated with the APOE genotype, which is also possibly associated with risk stratification. Further research is needed to confirm the potential prognostic value of these findings.PMID:38507115 | DOI:10.1007/s12185-024-03748-6 (Source: International Journal of Hematology)
Source: International Journal of Hematology - March 20, 2024 Category: Hematology Authors: Maria Ioannidou Chrysostomos Avgeros Elisavet Georgiou Aliki Papadimitriou-Tsantarliotou Dimitrios Dimitriadis Athanasios Tragiannidis Paraskevi Panagopoulou Evgenia Papakonstantinou Assimina Galli-Tsinopoulou Kali Makedou Emmanuel Hatzipantelis Source Type: research

Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of children being treated for acute lymphoblastic leukemia
CONCLUSIONS: Lipid abnormalities in children being treated for ALL may be associated with the APOE genotype, which is also possibly associated with risk stratification. Further research is needed to confirm the potential prognostic value of these findings.PMID:38507115 | DOI:10.1007/s12185-024-03748-6 (Source: International Journal of Hematology)
Source: International Journal of Hematology - March 20, 2024 Category: Hematology Authors: Maria Ioannidou Chrysostomos Avgeros Elisavet Georgiou Aliki Papadimitriou-Tsantarliotou Dimitrios Dimitriadis Athanasios Tragiannidis Paraskevi Panagopoulou Evgenia Papakonstantinou Assimina Galli-Tsinopoulou Kali Makedou Emmanuel Hatzipantelis Source Type: research